Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of Cat-PAD peptide immunotherapy for cat allergy
2012-001733-13Phase 3Completed
- Sponsor
- NIOX Group
- Start
- Aug 2012
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC) and perennial rhinitis comparing Cat-PAD with Placebo (2 arms). Primary endpoint: Mean Combined Score. Started Aug 2012; status: completed.
02
Drugs
Cat-PAD
03
Conditions
allergic rhinoconjunctivitis (ARC)perennial rhinitis
Beyond the preview
Go deeper on 2012-001733-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001733-13.